Photo of Philip C. Amrein,  MD

Philip C. Amrein, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-8748
Fax: (617) 724-3166


pamrein@partners.org

Philip C. Amrein, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Physician, Medicine Service, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research focus has been in the treatment of patients with acute and chronic leukemia. I have also participated in clinical trials for patients with myelodysplasia and multiple myeloma. The following is a list of clinical trials that I am most interested in accruing patients to:

1) DF/HCC protocol 06-254, which tests a new sequence of drugs for acute lymphoid leukemia

2) DF/HCC protocol 05-308 and CALGB 10303, which compares the effectiveness of dasatinib to standard therapy imatinib for CML in chronic phase

3) CALGB 10502, which tests the addition of bortezomib to standard treatment in acute myeloid leukemia

4) DF/HCC protocol 06-211, which tests the effectiveness of dasatinib in relapsed chronic lymphocytic leukemia

Publications

Powered by Harvard Catalyst
  • DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2015; 29:526-34. PubMed
  • Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, J√§nne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160:977-89. PubMed
  • Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. Leuk Res 2014; 38:773-80. PubMed
  • Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M, Sirulnik LA, Galinsky I, Golub T, Stegmaier K, Stone RM. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res 2014; 38:430-4. PubMed
  • Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 2014; 28:479-90. PubMed
  • Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res 2013; 37:1016-20. PubMed
  • Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Scd DS, Fathi AT. Association between baseline body mass index (BMI) and overall survival among patients over age 60 with acute myeloid leukemia (AML). Am J Hematol 2013. PubMed
  • Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, Deangelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. J Clin Oncol 2012. PubMed
  • Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012. PubMed
  • Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, McAfee SL, Dillon L, Chen YB, Hasserjian RP. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma 2012. PubMed
  • Amrein PC. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymphoma 2011. PubMed
  • Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR. Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res 2011. PubMed
  • Farris AB, Hasserjian RP, Zukerberg LR, Amrein PC, Greene RE, Mark EJ, Kradin RL. Diffuse cellular and fibrosing interstitial pneumonitis with desquamative interstitial pneumonitis-like features associated with myeloid neoplasia. Am J Surg Pathol 2010; 33:1485-93. PubMed
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518-25. PubMed
  • Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14:1446-54. PubMed
  • Meyer GS, Hales CA, Amrein PC, Sharma A, Kradin RL. Case records of the Massachusetts General Hospital. Case 26-2007 - a 61-year-old man with recurrent fevers. N Engl J Med 2007; 357:807-16. PubMed
  • Moore SD, Offor O, Ferry JA, Amrein PC, Morton CC, Dal Cin P. ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22). Leuk Res 2005; 30:1037-42. PubMed
  • Amrein PC, Clark JR, Supko JG, Fabian RL, Wang CC, Colevas AD, Posner MR, Deschler DG, Rocco JW, Finkelstein DM, McIntyre JF. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer 2005; 104:1418-27. PubMed
  • Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2004; 105:3420-7. PubMed
  • Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 2004; 10:2222-30. PubMed
  • Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res 2003; 9:5178-86. PubMed
  • Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer 2000; 88:2037-41. PubMed
  • Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2001; 95:2530-5. PubMed
  • Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17:3503-11. PubMed
  • Lee EJ, George SL, Amrein PC, Paciucci PA, Allen SL, Schiffer CA. An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B. Leukemia 1998; 12:139-43. PubMed
  • Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, Godfrey S, Robert F, Schiffer CA. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997; 89:780-8. PubMed
  • Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg 1997; 123:34-40. PubMed
  • Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 1993; 71:2326-31. PubMed
  • Amrein PC, Fabian RL. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate. Laryngoscope 1992; 102:901-6. PubMed
  • Gerard EL, Ferry JA, Amrein PC, Harmon DC, McKinstry RC, Hoppel BE, Rosen BR. Compositional changes in vertebral bone marrow during treatment for acute leukemia: assessment with quantitative chemical shift imaging. Radiology 1992; 183:39-46. PubMed
  • Rybak ME, Anderson JR, Poulin RF, Amrein PC, Canellos GP, Gottlieb AJ. Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972. Cancer Treat Rep 1986; 70:1233-4. PubMed
  • Amrein PC, Weitzman SA. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985; 3:1632-9. PubMed
  • Amrein PC, Coleman M, Richards F, Bhardwaj S, Kennedy BJ, Haurani FI, Frelick RW, Pastmantier MW, Herschkopf R. Treatment of metastatic ovarian carcinoma with amsacrine: a cancer and leukemia group B phase II study. Cancer Treat Rep 1984; 68:1397-8. PubMed
  • Amrein PC, Richards F, Coleman M, Poulin RF, Holland JF, Weinberg V, Perry M. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study. Cancer Treat Rep 1984; 68:923-4. PubMed
  • Amrein PC, Poulin RF, Coleman M, Richards F, Weil M, Kennedy BJ, Carey RW, Green MR, Holland JF, Weinberg V. The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. Am J Clin Oncol 1984; 7:269-71. PubMed
  • Amrein PC, Coleman M, Richards F, Poulin RF, Berkowitz I, Kennedy BJ, Green M, Herschkopf R, Rafla S. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study. Cancer Treat Rep 1983; 67:1043-4. PubMed
  • Amrein PC, Fingert H, Weitzman SA. Cisplatin-vincristine-bleomycin therapy in squamous cell carcinoma of the head and neck. J Clin Oncol 1983; 1:421-7. PubMed
  • Niederman R, Amrein PC, Hartwig J. Three-dimensional structure of actin filaments and of an actin gel made with actin-binding protein. J Cell Biol 1983; 96:1400-13. PubMed
  • Amrein PC, Kumar JR, Poulin RF, Umlas J, Weitzman SA. Comparison of filtration leukapheresis and centrifugation leukapheresis in treatment of lymphosarcoma cell leukemia. South Med J 1982; 75:969-71. PubMed
  • Amrein PC, Coleman M, Richards F, Poulin RF, Bernhardt B, Ginsberg SJ, Green MR, Morrison A, Cortes E, Kiang D, Weinberg V, Wood WC. Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Cancer Treat Rep 1982; 66:1211-3. PubMed
  • Amrein PC, Ellman L, Harris WH. Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA 1981; 245:1825-8. PubMed
  • Amrein PC, Friedman R, Kosinski K, Ellman L. Hematologic changes in anorexia nervosa. JAMA 1979; 241:2190-1. PubMed
  • Amrein PC, Larson SM, Wagner HN. A rapid automated system for measurement of antibody titers. J Nucl Med 1974; 15:1145-8. PubMed
  • Amrein PC, Larson SM, Wagner HN. An automated system for measurement of leukocyte metabolism. J Nucl Med 1974; 15:352-5. PubMed
Hide